Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gao, Feng Hou ^a   Hu, Xiao Hui ^a   Li, Wei ^c   Liu, Hua ^d   Zhang, Yan Jie ^a   Guo, Zhu Ying ^a   Xu, Mang Hua ^a   Wang, Shi Ting ^a   Jiang, Bin ^a   Liu, Feng ^a   Zhao, Ying Zheng ^c   Fang, Yong ^a   Chen, Fang Yuan ^e   Wu, Ying Li ^b  

^a School of Medicine   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DNA NUCLEOTIDYLEXOTRANSFERASE; HISTONE H3; HISTONE H4; MESSENGER RNA; MYC PROTEIN; ORIDONIN; PROTEIN P16; PROTEIN P21; PROTEIN P27; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE; KAURANE DERIVATIVE; P16 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR PROTEIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN STRUCTURE; COLONY FORMATION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL AGING; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ACETYLATION; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; CELL AGING; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DITERPENES, KAURANE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 78049385776     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-610     Document Type: Article

References (42)

1. Boursi B, Arber N. Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des 2007, 13(22):2274-2282. 10.2174/138161207781368783, 17692000.
2. Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009, 3(2):131-144. 10.1586/egh.09.8, 19351284.
3. Hebbar M, Ychou M, Ducreux M. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2009, 135(6):749-752. 10.1007/s00432-009-0580-x, 19343364.
4. Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 2009, 11(3):200-208. 10.1007/s11912-009-0029-z, 19336012.
5. Mihaylova Z, Raynov J. Neoadjuvant chemotherapy and targeted therapy in patients with liver metastases from colorectal cancer; medical oncologist's point of view. J BUON 2008, 13(3):323-331.
6. McGarvey DJ, Croteau R. Terpenoid metabolism. Plant Cell 1995, 7(7):1015-1026. 10.1105/tpc.7.7.1015, 160903, 7640522.
7. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci 2008, 65(19):2979-2999. 10.1007/s00018-008-8103-5, 18516495.
8. Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, Wang W. Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 2005, 116(5):799-807. 10.1002/ijc.20880, 15849732.
9. Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, Kim YS, Lee JH, Seo HG, Chang KC, Kim HJ. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 2008, 33(3):485-491.
10. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109(7):2727-2735.
11. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 2005, 337(1):224-231. 10.1016/j.bbrc.2005.09.040, 16176802.
12. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005, 4(4):578-586. 10.1158/1535-7163.MCT-04-0277, 15827331.
13. Liu J, Yang F, Zhang Y, Li J. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra. Int Immunopharmacol 2007, 7(7):945-954. 10.1016/j.intimp.2007.03.001, 17499197.
14. Gao F, Tang Q, Yang P, Fang Y, Li W, Wu Y. Apoptosis inducing and differentiation enhancement effect of oridonin on the all-trans-retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. Int J Lab Hematol 2010, 32(1 Pt 1):e114-122. 10.1111/j.1751-553X.2009.01147.x, 19302235.
15. Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 2004, 10(3):1150-1159. 10.1158/1078-0432.CCR-0747-3, 14871995.
16. Schmitt CA. Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer 2003, 3(4):286-295. 10.1038/nrc1044, 12671667.
17. Gao FH, Wang Q, Wu YL, Li X, Zhao KW, Chen GQ. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression. Biochem Biophys Res Commun 2007, 356(2):505-511. 10.1016/j.bbrc.2007.03.009, 17367753.
18. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113(6):703-716. 10.1016/S0092-8674(03)00401-X, 12809602.
19. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002, 62(17):4996-5000.
20. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109(3):335-346. 10.1016/S0092-8674(02)00734-1, 12015983.
21. Wong SC, Chan JK, Lee KC, Hsiao WL. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol 2001, 194(1):35-42. 10.1002/path.838, 11329139.
22. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005, 8(1):19-30. 10.1016/j.devcel.2004.10.019, 15621527.
23. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999, 59(15):3761-3767.
24. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108(2):153-164. 10.1016/S0092-8674(02)00625-6, 11832206.
25. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 2008, 107(4):370-379. 10.1254/jphs.08044FP, 18719315.
26. Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther 2007, 6(2):261-268. 10.4161/cbt.6.2.3621, 17218775.
27. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007, 109(8):3441-3450. 10.1182/blood-2006-06-032250, 1852250, 17197433.
28. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 2009, 490(1):70-75. 10.1016/j.abb.2009.08.011, 19699177.
29. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61(5):1957-1963.
30. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23(16):2919-2933. 10.1038/sj.onc.1207518, 15077154.
31. Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T, Kato H, Furugen Y, Yoshida K, Kato K, et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer 2001, 94(2):257-267. 10.1002/ijc.1448, 11668507.
32. Vigneron A, Roninson IB, Gamelin E, Coqueret O. Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005, 65(19):8927-8935. 10.1158/0008-5472.CAN-05-0461, 16204065.
33. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 2007, 12:4839-4854. 10.2741/2432, 17569614.
34. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008, 7(12):1745-1762. 2593475, 18594202.
35. Masramon L, Arribas R, Tortola S, Perucho M, Peinado MA. Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer. Br J Cancer 1998, 77(12):2349-2356. 2150408, 9649157.
36. Lagerholm S, Dutta S, Nair P. Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol 2005, 40(11):1343-1350. 10.1080/00365520510023549, 16334444.
37. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci 2006, 97(1):57-63. 10.1111/j.1349-7006.2006.00137.x, 16367922.
38. Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L. Making decisions through Myc. FEBS Lett 2001, 490(3):153-162. 10.1016/S0014-5793(01)02118-4, 11223030.
39. Karpinski P, Sasiadek MM, Blin N. Aberrant epigenetic patterns in the etiology of gastrointestinal cancers. J Appl Genet 2008, 49(1):1-10.
40. Konishi K, Issa JP. Targeting aberrant chromatin structure in colorectal carcinomas. Cancer J 2007, 13(1):49-55. 10.1097/PPO.0b013e31803c72fe, 17464246.
41. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004, 23(1-2):29-39. 10.1023/A:1025806911782, 15000147.
42. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009, 280(2):233-241. 10.1016/j.canlet.2009.02.019, 19344997.